BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the organization is in the process of working with market makers to move the trading of its common shares to the OTCBB quotation system. This comes about as a result of the recent completion of full financial audits for the years 2005 through 2009 and the filing of Form 10K with the U.S. Securities and Exchange Commission. BioElectronics is now a fully reporting company.
"Considering our new fully reporting status, our substantially enhanced balance sheet and the significant revenue growth we plan to realize on the short-term horizon. We believe it is appropriate for us to now move the trading of our shares to the OTCBB quotation system," commented Andrew Whelan, CEO of BioElectronics Corp. "This action will result in improved liquidity for our investors and will allow BioElectronics increased flexibility on many fronts. It is truly an exciting time for all of us at the Company as our revenue growth prospects continue to strengthen and as we take the necessary steps to move the trading of our shares in order to maximize shareholder value."
Research validates anti-inflammatory properties of wine using urinary tartaric acid as biomarker